Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three
different doses (30 or 40 or 50 mg). Vinorelbine will be administered orally at a metronomic
schedule three times a week: on Monday, Wednesday and Friday.